Tyrosine kinase inhibitor use and risk of neurodegenerative disease: A Swedish population‐based cohort study
Alzheimer's & Dementia · 2026-10 · 22 (10)
DOI: 10.1002/alz.71916 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Alzheimer's & Dementia, online erschienen am 11.10.2026. Verfasst von Felix Wittström und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre For Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION Effective disease‐modifying therapies remain unavailable for neurodegenerative diseases (NDDs). Tyrosine kinase inhibitors (TKIs) indicated for chronic myeloid leukemia (CML) have been hypothesized to modulate the pathological mechanisms underlying neurodegeneration. Therefore, we aimed to explore the association between initiation of six different TKIs and the subsequent risk of developing NDDs in Swedish nationwide registries (2005–2024). METHODS CML patients ≥50 years at diagnosis initiating TKI therapy were identified, alongside five comparators without CML matched on sex, age, and residence at diagnosis. CML cases and comparators were followed from the initiation date of the respective TKI and could contribute follow‐up time to multiple TKI cohorts. A composite measure of NDD diagnosis or death due to NDD was the outcome. Hazard ratios (HRs) were estimated using Cox proportional hazards models, with adjustments for calendar year at follow‐up initiation, and relevant comorbidities. RESULTS A total of 1322 CML cases were included in the study. 1188 initiated imatinib (of which 41 experienced an NDD event), 541 dasatinib (15 events), 390 nilotinib (five events), 174 bosutinib, 71 ponatinib, and 41 asciminib. Adjusted hazard ratios comparing each TKI group to their matched comparator populations were 0.98 (95% confidence interval [CI], 0.71 to 1.36) for imatinib users, 1.18 (95% CI, 0.68 to 2.03) for dasatinib users, and 0.37 (95% CI, 0.15 to 0.90) for nilotinib users. Bosutinib, ponatinib, and asciminib users were too few to conduct comparative analyses. DISCUSSION Initiation of nilotinib, but not imatinib or dasatinib, was associated with a significantly lower NDD incidence relative to general population comparators.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre For Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- German Center for Neurodegenerative Diseases (DZNE), Greifswald, Germany.
- Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden.
ORCID-Profile: Felix Wittström
Zitieren
APA
Wittström, F., Chen, E. Y., Blotenberg, I., & Dahlén, T. (2026). Tyrosine kinase inhibitor use and risk of neurodegenerative disease: A Swedish population‐based cohort study. Alzheimer's & Dementia, 22(10). https://doi.org/10.1002/alz.71916
Vancouver
Wittström F, Chen EY, Blotenberg I, Dahlén T. Tyrosine kinase inhibitor use and risk of neurodegenerative disease: A Swedish population‐based cohort study. Alzheimer's & Dementia. 2026;22(10). doi:10.1002/alz.71916
BibTeX
@article{Wittstrm2026,
author = {Wittström, Felix and Chen, Enoch Yi-Tung and Blotenberg, Iris and Dahlén, Torsten},
title = {Tyrosine kinase inhibitor use and risk of neurodegenerative disease: A Swedish population‐based cohort study},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {10},
doi = {10.1002/alz.71916}
}
EUVIMED